Latest news with #DiabetesAtlas
Yahoo
30-05-2025
- Business
- Yahoo
Continuous Glucose Monitoring Devices Market Size expected to reach US$ 32.97 billion by 2031, Increasing Demand for Effective Diabetes Management Propels Growth
The Continuous Glucose Monitoring (CGM) devices market, valued at $12.63 billion in 2024 and projected to reach $32.97 billion by 2031, is growing at a 12.6% CAGR, driven by rising diabetes prevalence, home-based care, and technological advancements, with key players including Dexcom, Abbott, Medtronic, and Senseonics leading innovation in real-time, wearable, and non-invasive monitoring solutions. US & Canada, May 30, 2025 (GLOBE NEWSWIRE) -- According to a new comprehensive report from The Insight Partners, the global continuous glucose monitoring devices market is observing significant growth owing to the increasing demand for effective diabetes management and the growing use of OTC products. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the continuous glucose monitoring devices market comprises a vast array of products and services that are expected to register strength in the coming years. To explore the valuable insights in the Continuous Glucose Monitoring Device Market report, you can easily download a sample PDF of the report - Overview of Report Findings Market Growth: The continuous glucose monitoring devices market is expected to reach US$ 32.97 billion by 2031 from US$ 12.63 billion in 2024, at a CAGR of 12.6% during the forecast period. Continuous glucose monitoring devices (CGMD) represent the most advanced technology for managing diabetes manually, featuring components such as sensors, transmitters, and monitors. These devices offer real-time updates on blood sugar levels. This information allows individuals to adjust their dietary choices or insulin doses as recommended by their healthcare provider. By providing real-time data, these devices help reduce the risk of hypoglycemia and hyperglycemia in those living with diabetes. Increasing Need for Effective Diabetes Management: Diabetes, especially type 2, is a growing global concern, with countries such as India seeing a significant increase. As per the International Diabetes Federation (IDF) Diabetes Atlas, ~10.5% of adults globally aged 20–79 years had diabetes in 2021. This number is projected to rise to 12.2% by 2045. According to the World Health Organization (WHO), ~77 million people aged 18 and older in India were living with diabetes, while ~25 million were considered pre-diabetic in 2022. This increasing incidence underscores the urgent need for proactive products and tools for advanced, user-friendly monitoring, such as CGM devices, to address the issue. CGM systems offer real-time insights into glucose levels, allowing users to make quick decisions about diet, exercise, and medication. This ongoing data helps achieve better blood sugar control, lower HbA1c levels, and prevent hypoglycemia, organ damage, etc. By detecting glucose fluctuations early—often before symptoms arise—CGM empowers patients and healthcare providers to intervene effectively. Surging Use of OTC Products: The availability of over-the-counter (OTC) CGM devices has greatly increased market growth by making glucose monitoring more accessible and affordable. Since these devices don't require prescriptions, individuals can easily purchase them from pharmacies, online retailers, or supermarkets. This convenience has led to widespread use among people with diabetes, those at risk, and health-conscious individuals looking to monitor their well-being. In March 2024, the US Food and Drug Administration (FDA) accepted the first OTC continuous glucose monitor (CGM) for marketing. The Dexcom Stelo Glucose Biosensor System is an integrated CGM (iCGM) designed for individuals aged 18 and older who do not use insulin. This includes people with diabetes managing their condition with oral medications, as well as those without diabetes who want to understand the effect of diet and exercise on blood sugar levels. Geographical Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and APAC. Asia Pacific is expected to register the highest CAGR during the forecast period. For Detailed Continuous Glucose Monitoring Device Market Insights, Visit: Market Segmentation Based on product, the continuous glucose monitoring devices market is segmented into sensors, transmitters, and receivers. The sensors segment held the largest share of the continuous glucose monitoring devices market in 2024. Based on testing sites, the continuous glucose monitoring devices market is bifurcated into fingertip testing and alternate site testing. The fingertip testing segment held a larger share of the continuous glucose monitoring devices market in 2024. In terms of application, the continuous glucose monitoring devices market is bifurcated into type-1 diabetes and type-2 diabetes. The type-2 diabetes segment held a larger share of the continuous glucose monitoring devices market in 2024. In terms of end user, the continuous glucose monitoring devices market is bifurcated into hospitals and clinics and self/home care. The hospitals and clinics segment held a larger share of the continuous glucose monitoring devices market in 2024. The continuous glucose monitoring devices market is segmented into five major regions: North America, Europe, APAC, Middle East and Africa, and South and Central America. Competitive Strategy and Development Key Players: A few major companies operating in the continuous glucose monitoring devices market include B. Braun SE, F. Hoffmann-La-Roche Ltd, LifeScan Inc, Medtronic, Abbott Laboratories, Ypsomed Holding AG, Sensionics, Nipro Corp, GE Healthcare, and Novo Nordisk A/S. Trending Topics: Advanced Continuous Glucose Monitoring Devices, AI in Continuous Glucose Monitoring Devices, Type-2 Diabetes Management, and OTC Devices for Continuous Glucose Management, among others. Stay Updated on The Latest Continuous Glucose Monitoring Device Market Trends: Global Headlines on Continuous Glucose Monitoring Devices Philips-Medisize announced a partnership with GlucoModic to commercialize a proprietary non-invasive and wearable device. This partnership aims to develop a solution that is needle-free, accurate, and more affordable for diabetic patient to monitor their blood glucose levels. Medtronic received CE Mark approval for the "MiniMed 780G system" with the Simplera Sync, a disposable all-in-one Continuous Glucose Monitoring device that requires no finger pricks or overtaping. This new product will be available in Europe, with a phased commercial launch planned for Spring 2024. Dexcom launched a new Continuous Glucose Monitoring device, the "Dexcom G7." This device is the smallest and most accurate Continuous Glucose Monitoring option connected to the t:slim X2 insulin pump. The Dexcom G7 has the fastest sensor warm-up time at just 30 minutes and, along with the Dexcom G6, is the only Continuous Glucose Monitoring system capable of providing alerts without the need for finger pricks. Roche received the CE Mark for its AI-enabled continuous glucose monitoring solution, the Accu-Chek SmartGuide CGM. This device offers accurate real-time glucose readings for 14 days, helping adults with type 1 and type 2 diabetes with flexible insulin therapy. Purchase Premium Copy of Global Continuous Glucose Monitoring Device Market Size and Growth Report (2020-2031) at: Conclusion The growing prevalence of diabetes and rising use of OTC products for self-management drive the continuous glucose monitoring devices market growth. The utilization of Continuous Glucose Monitoring (CGM) systems has broadened its scope beyond insulin-dependent individuals to encompass those with type 2 diabetes, as well as health-conscious non-diabetics. This expansion is attributed to technological advancements such as smartphone integration, artificial intelligence, and non-invasive sensor technology. Adoption barriers are being removed by increased insurance coverage, OTC access, and other regulatory reforms, especially in large countries, including the US and Europe. Due to increased accessibility, cost, and user empowerment, the shift to OTC availability has democratized glucose monitoring, greatly expanding the industry and fostering long-term market growth. Talk to Us Directly: Related Reports: About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit Mathur E-mail: Phone: +1-646-491-9876 Home - in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Mint
20-05-2025
- Health
- Mint
Mounjaro in India: The speed bumps impacting access to weight loss drugs
The immensely successful new age weight loss jabs have finally come to India with the recent launch of Eli Lilly's Mounjaro and more are likely to be launched in the due course of time. These drugs couldn't have come at a more critical moment as India is staring down the barrel of a double engine public health crisis of rising cases of diabetes and obesity. Also read: Obesity's new spin: is it time to say 'bye BMI'? India finds itself in the second spot on a far-from-flattering obesity list. With 180 million, India had a higher incidence of obesity than the USA, which came third with 172 million, as per the Global Burden of Disease Study 2021. China tops that list with 402 million obese adults. Things are only going to get worse, as per a forecasting study published in The Lancet in March this year, which estimated that more than half of the world's population — 3.8 billion adults and 746 million children and young adults — will be obese or overweight by the year 2050 if urgent action isn't taken. India also has the second highest number of adults (20-79 years) with diabetes in the world with almost 90 million adults afflicted in the country, according to the latest Diabetes Atlas report. By 2050, this number is forecast to go up to 156.7 million. The new age injectable obesity drugs such as Mounjaro (tirzepatide), Ozempic and Wegovy (both semaglutide) are intended for individuals with obesity, particularly those with co-morbidities such as diabetes, hypertension, heart disease, and arthritis. In India, these weight-loss jabs are not over-the-counter drugs and require a doctor's prescription, says Dr. Sanjay Khare, director for bariatric medicine, Apollo Hospitals Navi Mumbai. However, doctors also acknowledge that a black market for these drugs has existed in the country and a prescription is not the only way to access them. 'Access to these medications requires a doctor's prescription, although some individuals may acquire them from local chemists or import them from neighbouring countries at a premium cost," adds Khare. These drugs are pivotal for India due to the escalating obesity and diabetes epidemics, which are contributing significantly to related health issues. Khare contends that the ground reality is that obesity rates in India are even higher than national estimates and that obesity cannot be cured by the simplistic eat-less-exercise-more guideline. 'The introduction of weight loss drugs like Mounjaro presents a promising medical tool to combat these twin epidemics… these drugs can play a pivotal role in managing and reducing the burden of non-communicable diseases in India," feels says Dr. Sukhvinder Singh Saggu, director for minimal access, gastro-intestinal and bariatric surgery, CK Birla Hospital, New Delhi. Both tirzepatide and semaglutide-based weight loss injectables regulate users' appetite and make them feel full after eating by triggering the glucagon-like peptide-1 (GLP-1) hormone in the small intestine. Also read: What body positivity means in the age of Ozempic 'GLP-1 is the hormone produced in the gut after food reaches the ileum. These drugs also sensitize the pancreas to secrete more insulin leading to improved insulin sensitivity and decreases insulin resistance. It increases energy expenditure and signals to the brain that stomach is full, which results in appetite suppression," explains Dr Manoj Jain, obesity surgeon and consultant for gastro-intestinal and laparoscopic general surgery at Kokilaben Dhirubhai Ambani Hospital, Mumbai. Typically, patients are administered one jab per week during the entire duration of the treatment. Multiple studies and findings presented at last week's European Congress on Obesity in Spain made abundantly clear that the benefits of these drugs go way beyond mere weight loss, improving insulin sensitivity and managing diabetes. A study published in January found that weight-loss jabs could reduce the risk of 42 diseases including cancer, cardiovascular diseases, Alzheimer's, chronic kidney disease, addiction and psychiatric conditions too. Separate studies have also found that these drugs significantly cut the risk of obesity-related cancers and also have mental health benefits. However, one of the biggest hurdles in effectively utilising these new drugs to tackle India's obesity and diabetes problems is their high price. 'These weight loss jabs are relatively expensive and may not be affordable for a majority of Indians who require them," confirms Saggu. On average, they cost between ₹10,000 to ₹15,000 for a month's dosage. For now, there is limited coverage for these medicines under health insurance in India, putting this treatment out of reach for the majority of the our 1.4 billion population. 'This out-of-pocket cost poses a significant financial burden, especially considering the widespread prevalence of obesity and diabetes. There is a need for policy-level interventions such as pricing regulation or subsidised schemes to make these life-altering treatments more accessible to the broader population," Saggu adds. And among those who can afford them, weight loss drugs are being misused as lifestyle interventions to achieve desired aesthetic results in quick time. Both Khare and Saggu flag 'micro-dosing' of weight-loss drugs among people of means, including celebrities, as a worrying trend that is catching on. Also read: The rise of chrononutrition: why the timing of your meals matters more than ever Micro-dosing refers to using smaller, unprescribed doses of the drugs in an attempt to avoid medical scrutiny while achieving gradual weight loss. Since Mounjaro is the only injectable available in India as of now, the supply is limited forcing many 'micro-dosers" to procure these medications through unofficial channels or importing them from abroad without a prescription, bypassing necessary medical evaluation, say doctors. 'This can be extremely risky, as such use does not take into account individual health profiles, pre-existing conditions, or potential drug interactions," warns Saggu. Furthermore, multiple studies have reported side effects such as severe constipation, nausea, gastrointestinal issues, thyroid complications, cholesterol imbalances, and other metabolic disturbances. Drug companies do not track subjects once their testing ends, so you won't find the limitations of the drugs in their literature and research. However, there is just about enough real world evidence that suggests that the shed weight, invariably, comes back once the medication stops. At the European Congress on Obesity, experts said the weight gain begins within 10 weeks of discontinuing medication. Hence, despite them being extremely effective and with multiple benefits, new age weight loss drugs cannot replace a healthy lifestyle. 'While they are effective for weight loss, they do not replace the need for a balanced approach. These drugs are not a substitute for lifestyle changes but are valuable adjuncts to diet, exercise, and overall health management. Without significant lifestyle modifications, the drugs are unlikely to yield lasting results," says Khare. Shrenik Avlani is a writer and editor and the co-author of The Shivfit Way, a book on functional fitness. Also read: Want to counter cancer's side-effects? Get exercising
Korea Herald
07-04-2025
- Health
- Korea Herald
Over 250 million people worldwide unaware they have diabetes, according to new research from the International Diabetes Federation (IDF)
New estimates from the IDF Diabetes Atlas highlight the growing diabetes threat, with nearly one in nine adults now living with the condition. BRUSSELS, April 7, 2025 /PRNewswire/ -- Globally, nearly one in nine adults (589 million) are now living with diabetes. Of these, an estimated 252 million are not yet aware they have the condition, placing them at higher risk of serious complications and early death. Many will be diagnosed when they already have one or more of the associated complications and have missed opportunities to prevent or delay their onset. These alarming findings are from the 11 th edition of the International Diabetes Federation's Diabetes Atlas, released today at the start of the organisation's World Diabetes Congress in Bangkok, Thailand. The latest IDF estimates show that: As the number of people living with diabetes continues to rise, the latest IDF Diabetes Atlas emphasises the urgent need for improved prevention, early detection and intervention to tackle the burden diabetes places on individuals, communities, health systems and economies. In 2024, global diabetes-related health expenditure surpassed one trillion US dollars for the first time, up from $966 billion in 2021. First published in 2000, the IDF Diabetes Atlas offers insights into the impact of diabetes at national, regional, and global levels, based on the best available evidence. The 11 th edition reflects new methodologies that incorporate trends in health expenditure, regional prevalence rates, and a focus on undiagnosed diabetes. Commenting on the new edition, Professor Dianna Magliano, who co-Chairs the IDF Diabetes Atlas Committee along with Professor Edward Boyko, said: "The new data provides strong evidence that should spark action and promote initiatives to improve the lives of the many millions now living with diabetes and encourage more to detect diabetes in those at risk." Professor Boyko added: "Addressing the rising trend will require greater awareness, a focus on prevention and ongoing surveillance of diabetes prevalence to support accurate monitoring of the global diabetes impact." Diabetes is associated with serious complications, such as cardiovascular diseases, kidney failure, nerve damage and loss of vision. The latest data shows that people living with type 2 diabetes, which accounts for over 90% of all diabetes, are at 84% higher risk of heart failure than people who do not have the condition. The International Diabetes Federation warns that the alarming rise in the prevalence of diabetes demands immediate action. Governments should invest in preventive healthcare programmes, especially in regions where diabetes is often undiagnosed, to detect people at high risk early and help delay or avoid the onset of diabetes and its related complications. Speaking at the launch, IDF President Professor Peter Schwarz said: "The findings underscore an urgent need for bolder national and global action to tackle diabetes. With over 4 in every 10 people with diabetes not yet diagnosed, governments must prioritise screening, early diagnosis, and education. Addressing the rising tide of diabetes will demand collaboration across multiple sectors and disciplines. Governments, the healthcare sector, education, technology and the private sectors all have a role to play. The consequences of ignoring or not paying sufficient attention to the diabetes challenge are too significant. Inaction in the face of this pandemic is not an option." To explore the global, regional and national findings presented in the IDF Diabetes Atlas 11 th Edition, visit About the International Diabetes Federation The International Diabetes Federation (IDF) is an umbrella organisation of over 240 national diabetes associations in more than 160 countries and territories. Its mission is to improve the lives of people with diabetes and prevent diabetes in those at risk. The IDF Diabetes Atlas is the authoritative resource on the global impact of diabetes. First published in 2000, it is produced by the International Diabetes Federation (IDF) in collaboration with a global committee of scientific experts. It contains statistics on diabetes prevalence, diabetes-related mortality and health expenditure at the global, regional and national levels. The 11th edition has been produced thanks to educational grants from Sanofi, Novo Nordisk and MSD.
